Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | DRD2 | P14416 | 7/20 | 0.63 |
| ▸ | DRD3 | P35462 | 7/20 | 0.63 |
| ▸ | HTR1A | P08908 | 6/20 | 0.63 |
| ▸ | HTR2A | P28223 | 4/20 | 0.63 |
| ▸ | HTR7 | P34969 | 4/20 | 0.63 |
| ▸ | DRD1 | P21728 | 4/20 | 0.63 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.63 |
| ▸ | DRD5 | P21918 | 3/20 | 0.63 |
| ▸ | HRH1 | P35367 | 3/20 | 0.63 |
| ▸ | DRD4 | P21917 | 2/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30206433 | 1.00 | KCNH2 (0.71) | KCNH2POLBDRD2DRD3HTR1A | |
| SCHEMBL102892 | 0.92 | KCNH2 (0.64) | KCNH2POLBDRD2DRD3HTR1A | |
| SCHEMBL26108725 | 0.90 | KCNH2 (0.85) | KCNH2POLBDRD2DRD3HTR1A | |
| SCHEMBL4519313 | 0.90 | KCNH2 (0.85) | KCNH2POLBDRD2DRD3HTR1A | |
| SCHEMBL26107525 | 0.90 | KCNH2 (0.85) | KCNH2POLBDRD2DRD3HTR1A | |
| Hydrochloric Acid SCHEMBL26108256 | 0.89 | KCNH2 (0.83) | KCNH2POLBDRD2DRD3HTR1A | |
| SCHEMBL13711971 | 0.88 | KCNH2 (0.71) | KCNH2POLBDRD2DRD3HTR1A | |
| SCHEMBL1233437 | 0.86 | KCNH2 (0.69) | KCNH2POLBDRD2DRD3HTR1A | |
| SCHEMBL18301485 | 0.86 | KCNH2 (0.69) | KCNH2POLBDRD2DRD3HTR1A | |
| SCHEMBL5572065 | 0.86 | KCNH2 (0.69) | KCNH2POLBDRD2DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110511215-B | Aryl piperazine/piperidine compound and application thereof | 复旦大学 | 2023-03-28 | — | — | CN | disclosed |
| EP-1724267-B1 | PYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2013-11-06 | — | — | EP | disclosed |
| CN-1922171-B | Pyrimidine derivative | ASKA PHARM CO LTD | 2012-10-17 | — | — | CN | disclosed |
| US-7799775-B2 | such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| EP-0911330-B1 | 1-(4-Arylpiperazine-1-y1)-3-(2-oxopyrrolidin/piperidin-1-y1) propanes as therapeutic agents for hypertension, ischemia, cardiovascular and other adrenergic receptors related disorders | COUNCIL SCIENT IND RES (IN) | 2007-12-12 | — | — | EP | disclosed |
| US-20070197551-A1 | Pyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| CN-1922171-A | Pyrimidine derivatives | ASKA PHARM CO LTD (JP) | 2007-02-28 | — | — | CN | disclosed |
| EP-1724267-A1 | PYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2006-11-22 | — | — | EP | disclosed |
| EP-0913397-B1 | A proces for the synthesis of 1-(4-Arylpiperazine-1-y1)-3-(2-oxypyrrolidin/piperidin-1-yl)propanes as therapeutic agents for hypertension, ischemia, cardiovascular and other adrenergic receptors related disorders | COUNCIL SCIENT IND RES (IN) | 2006-07-05 | — | — | EP | disclosed |
| US-6084097-A | BY CONDENSING A PYRIDYL PIPERAZINE OR A SUBSTITUTED PHENYL PIPERAZINE WITH 1-CHLORO-3-(2-OXOPYRROLIDIN-1-YL)PROPANE OR 1-CHLORO-3-(2-OXOPIPERIDIN-1-YL)PROPANE IN THE PRESENCE OF A BASE, A CATALYST AND ORGANIC SOLVENT; ANTIHYPERTENSIVE AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2000-07-04 | — | — | US | disclosed |
| EP-0913397-A1 | A proces for the synthesis of 1-(4-Arylpiperazine-1-y1)-3-(2-oxypyrrolidin/piperidin-1-y1) propanes as therapeutic agents for hypertension, ischemia, cardiovascular and other adrenergic receptors related disorders | Council of Scientific and Industrial Research (IN) | 1999-05-06 | — | — | EP | disclosed |
| EP-0911330-A1 | 1-(4-Arylpiperazine-1-y1)-3-(2-oxopyrrolidin/piperidin-1-y1) propanes as therapeutic agents for hypertension, ischemia, cardiovascular and other adrenergic receptors related disorders | Council of Scientific & Industrial Research (IN) | 1999-04-28 | — | — | EP | disclosed |
| EP-0109562-B1 | SUCCINIMIDE DERIVATIVES AND THEIR PRODUCTION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-09-02 | — | — | EP | disclosed |
| US-4598078-A | N-(substituted piperazinyl) alkylbicyclic succinimide derivatives | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1986-07-01 | — | — | US | disclosed |
| EP-0109562-A1 | Succinimide derivatives and their production | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197551-A1 | Pyrimidine derivatives | HTR3B, HTR3A, HTR1A | KCNH2 616/4885POLB 2349/4885DRD2 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.